Press Release

Acquisition extends Millipore’s biopharmaceutical services offering to European market

BILLERICA, Mass.--(BUSINESS WIRE)--Aug. 10, 2009-- Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today announced it has acquired BioAnaLab, a European-based services provider that specializes in the analysis of biologic drugs and vaccines. The transaction enables Millipore to expand its biopharmaceutical services business into Europe and further strengthens its position as a preferred outsource partner to biopharmaceutical companies.

“As an increasing number of biologics enter the pipeline, companies are leveraging Millipore’s ligand binding assay expertise to help them evaluate the efficacy of these drugs and achieve regulatory compliance,” said Jonathan DiVincenzo, President of Millipore’s Bioscience Division. “Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market. BioAnaLab will add cGMP support testing capabilities to our portfolio, a solid customer base, and a team of highly talented services professionals with expertise in emerging scientific disciplines.”

Based in Oxford, United Kingdom, BioAnaLab was spun out of the University of Oxford in 2002 to meet the unique requirements of the biopharmaceutical industry. The Company helps its customers better understand the safety and efficacy of biologic drugs and vaccines by providing a broad range of services to assist with evaluating and advancing these therapeutics from the drug development pipeline to the market. Services offered by BioAnaLab include assay transfer/development, validation & sample analysis, pharmacokinetics/ toxicokinetics, immunogenicity, biological potency, and vaccine services. Millipore will bring substantial expertise in biomarker analytical services to strengthen BioAnaLab’s current offering in that area.

“We are excited to join forces with Millipore as we work to become the world’s leading provider of large molecule bioanalytical services,” said Geoff Hale, Ph.D., Founder and CEO of BioAnaLab. “Through Millipore’s global market presence, we will add new capabilities and increase our capacity to serve our customers across the world. I am particularly pleased to be joining a company that shares our passion for combining top scientific expertise with an uncompromising commitment to quality."

BioAnaLab’s facility in Oxford, UK will complement Millipore’s existing facility for large molecule bioanalytical services in St. Charles, Missouri. Both facilities are audited by their national regulatory agencies. Geoff Hale will remain with Millipore and become Director of Biopharma Services in Europe. He will work closely with Ron Bowsher, Ph.D., Millipore’s Chief Scientist for Biopharmaceutical Services in the United States who recently received a prestigious award for his ground-breaking work in the industry.

About Millipore

Millipore (NYSE: MIL) is a life science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees in 30 countries worldwide.

Advancing Life Science Together™

Research. Development. Production.

Forward Looking Statements:

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug; delay, suspension or termination of a customer’s volume production; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of customers’ therapeutics; limitations on cash flow available for operations and investment due to increased debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for animal-derived cell culture products; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; the inability to achieve anticipated cost benefits of our supply chain initiatives; risks relating to our concentration of principal manufacturing operations; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

Source: Millipore Corporation

Millipore Corporation
Joshua Young, 978-715-1527 or 800-225-3384
Director, Investor Relations
joshua_young@millipore.com
or
Millipore Corporation
Karen Hall, 978-715-1567
Director, Corporate Communications
karen_hall@millipore.com